Press Release
RepliCel Announces Details of its Annual General Meeting
4 years ago
Dec 01, 2020 
VANCOUVER, BC, CANADA – December 1, 2020 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company announced details on how interested parties may participate in and exercise votes prior to its annual general meeting "AGM". In response to the unprecedented public health impact of COVID-19, to ensure the safety of its shareholders, employees, and service providers, the Company has decided to hold its annual general meeting as an exclusively virtual event.
Participation is open to all interested parties. Management will be making a presentation and questions can be posed to management at the conclusion of the AGM.
Shareholders who wish to exercise their vote must do so before the AGM by proxy or voting instruction form prior to the proxy cut-off on Friday, December 4 at 16:30 Pacific Standard Time.
For access to all shareholder materials for the AGM including the information circular, voting instruction form, form of proxy, financial statements request form, and notice of meeting, see online at https://www.replicel.com/About/fact-sheets.
AGM Details
Date: Tuesday, 8 December 2020 (Vancouver)
Time: 16:30 Pacific Time, 17:30 Mountain, 18:30 Central, 19:30 Eastern
01:30 (Wednesday, 9 December) CET
08:30 (Wednesday, 9 December) China
09:30 (Wednesday, 9 December) Japan
Zoom: Join the meeting by Zoom Meeting using the following link: https://us02web.zoom.us/j/85659665523?pwd=THMzbG9rdXREMHdPOW5RMmg1NnNBUT09
Meeting ID: 856 5966 5523.
Passcode: RCH1
Telephone:
Canada +1 778 907 2071 +1 204 272 7920 +1 438 809 7799 +1 587 328 1099 +1 647 374 4685 +1 647 558 0588
Germany +49 69 7104 9922 +49 30 5679 5800 +49 69 3807 9883 +49 695 050 2596
Japan +81 524 564 439 +81 3 4578 1488 +81 363 628 317
UK +44 203 901 7895 +44 131 460 1196 +44 203 051 2874 +44 203 481 5237 +44 203 481 5240
USA +1 929 205 6099 (New York) +1 253 215 8782 (Tacoma) +1 312 626 6799 (Chicago)
+1 346 248 7799 (Houston) +1 669 900 6833 (San Jose) +1 301 715 8592 (Washington D.C)
Find other local numbers here: https://us02web.zoom.us/u/ketjq3MAxp
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function.
The Company’s product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RepliCel has also developed a proprietary injection device, RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications. RCH-01 is currently being co-developed with, and under exclusive license by, Shiseido for certain Asian countries. All product candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s healthy hair follicles.
For more information, please visit www.replicel.com or contact:
Lee Buckler, CEO and President
604-248-8693 info @replicel .com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.